Latest Health News

Globe Metals & Mining has issued over 56 million shares to Director Bo Tan, settling nearly all of an outstanding loan and achieving a fully debt-free status. This financial milestone positions the company strongly for advancing its Kanyika Niobium Project.

Neurizon Therapeutics has launched a A$24.2 million equity raise to fund the next phase of clinical trials for its lead drug NUZ-001 targeting ALS, supported by a global licensing deal and a flexible convertible note facility.

Artrya Limited has signed a significant five-year commercial agreement with Cone Health, marking its third U.S. customer and solidifying its foothold in the American healthcare market with its AI-powered Salix platform.

Larvotto Resources has initiated underground development at its Hillgrove Antimony-Gold Project, marking a pivotal step toward resuming production with a comprehensive four-year plan.

VRX Silica Limited has announced a strategic leadership transition with Tony Swiericzuk appointed as CEO, succeeding Bruce Maluish who will step down in 2026 but remain on the board. This move positions VRX to advance its Arrowsmith North silica sand project towards production.

Centuria Capital Group has announced an ordinary fully franked dividend of AUD 0.052 per security for the half-year ending December 2025, signaling steady income for investors.

Infratil Limited has achieved a significant milestone with S&P Global Ratings assigning it a BBB+ investment grade credit rating, signaling strong financial health and promising future expansion opportunities.

Little Green Pharma welcomes a landmark US Executive Order directing cannabis rescheduling, a move poised to reshape the global medicinal cannabis landscape.

CONNEQT Health has raised $3.1 million through an institutional placement to fuel growth of its Pulse vascular health device, supported by both new and existing investors including its largest shareholder.

Neuren Pharmaceuticals has secured Health Canada approval to expand its pivotal Phase 3 trial of NNZ-2591 for Phelan-McDermid syndrome into Canadian sites, complementing ongoing US enrolment.

Mayne Pharma reports mixed early FY26 results with strong prescription growth in Women’s Health and improved Dermatology margins, while strategic reviews and litigation loom.

Stockland has announced an estimated ordinary dividend of AUD 0.09 per security for the six months ending December 2025, payable in February 2026, alongside a Dividend Reinvestment Plan offering a 1% discount.